-
Something wrong with this record ?
MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?
T. Lopotová, M. Záčková, H. Klamová, J. Moravcová,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Fusion Proteins, bcr-abl antagonists & inhibitors MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics MeSH
- Genes, abl physiology MeSH
- Humans MeSH
- MicroRNAs genetics MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Chronic myeloid leukemia (CML) is caused by constituve activity of BCR-ABL tyrosine kinase. Despite of high efficiency of imatinib, selective BCR-ABL inhibitor, about 30% of patients develop resistance. Novel markers and targets for therapy are thus necessary. MicroRNAs are small intereference RNAs whose role in physiological and malignant hematopoiesis has been shown. This study is focused on miR-451 in CML. Following our observation of miR-451 downregulation in CML, we further show its relation to BCR-ABL activity. Our data together with current literature indicate a more complex relationship of miR-451 and BCR-ABL in CML.
Department of Molecular Genetics Institute of Hematology and Blood Transfusion Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027600
- 003
- CZ-PrNML
- 005
- 20121207122540.0
- 007
- ta
- 008
- 120817e20110420enk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.leukres.2011.03.029 $2 doi
- 035 __
- $a (PubMed)21511335
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Lopotová, Tereza $u Department of Molecular Genetics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic. tereza.lopotova@uhkt.cz
- 245 10
- $a MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop? / $c T. Lopotová, M. Záčková, H. Klamová, J. Moravcová,
- 520 9_
- $a Chronic myeloid leukemia (CML) is caused by constituve activity of BCR-ABL tyrosine kinase. Despite of high efficiency of imatinib, selective BCR-ABL inhibitor, about 30% of patients develop resistance. Novel markers and targets for therapy are thus necessary. MicroRNAs are small intereference RNAs whose role in physiological and malignant hematopoiesis has been shown. This study is focused on miR-451 in CML. Following our observation of miR-451 downregulation in CML, we further show its relation to BCR-ABL activity. Our data together with current literature indicate a more complex relationship of miR-451 and BCR-ABL in CML.
- 650 _2
- $a bcr-abl fúzní proteiny $x antagonisté a inhibitory $7 D016044
- 650 _2
- $a geny abl $x fyziologie $7 D016313
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická myeloidní leukemie $x genetika $7 D015464
- 650 _2
- $a mikro RNA $x genetika $7 D035683
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Záčková, Markéta
- 700 1_
- $a Klamová, Hana
- 700 1_
- $a Moravcová, Jana
- 773 0_
- $w MED00003141 $t Leukemia research $x 1873-5835 $g Roč. 35, č. 7 (20110420), s. 974-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21511335 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121207122614 $b ABA008
- 999 __
- $a ok $b bmc $g 949642 $s 784946
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 35 $c 7 $d 974-7 $e 20110420 $i 1873-5835 $m Leukemia research $n Leuk Res $x MED00003141
- LZP __
- $a Pubmed-20120817/11/03
